Untitled

Abstract

Introduction The Bone and Joint Monitor Project was developed to quantify the global burden of musculoskeletal conditions and develop strategies for their prevention. Experts within the Monitor Project have worked previously with officers at the World Health Organization (WHO) to estimate morbidity and mortality associated with rheumatic conditions. The present collaboration seeks means of providing additional and more current burden data. Objective To develop recommendations for performing epidemiological studies in sample populations with musculoskeletal conditions and problems, accounting for determinants and consequences to the individual and society. Methods Recommendations have been developed identifying the most relevant domains for measuring and monitoring the various musculoskeletal conditions by review of epidemiological data on occurrence, determinants and outcomes, and by expert opinion. Instruments that measure these domains were reviewed. Results The domains recommended follow the principles of the WHO International Classification of Functioning, Disability and Health [1,2], and consider: health condition; body function and structure; activity limitation; participation restriction; personal and environmental contextual factors; and, in addition, the resource utilisation and social consequences. The musculoskeletal conditions and problems considered were osteoarthitis, inflammatory arthritis, osteoporosis, spinal problems, musculoskeletal trauma and injuries, and musculoskeletal pain with restricted activity. The selection of indicators for each domain considered the feasibility of their use in a health interview survey (HIS), a health examination survey (HES), a register or a clinical study. Consensus on case definition was reached depending on the study methodology. For example, osteoporosis defined by bone densitometry cannot be ascertained in an HIS, whereas the outcome of osteoporosis (i.e. fragility fracture) can be. Osteoarthitis can be identified as joint pain in an HIS but the preferred definition is pain with X-ray changes and can only be ascertained in an HES. Previously validated generic and disease-specific instruments have been identified that include indicators for all or most of the recommended domains for the consequences of the different conditions and problems. The indicators of the domains for resource utilisation and social consequences and feasibility for collection will vary in different socioeconomic and geographic areas. Guidance on sampling methods is also being developed. Conclusions The comparability of data collected across the globe will improve by the application of agreed upon indicators that consider key domains for the different musculoskeletal conditions and problems in epidemiological studies conducted in different populations.

Pathobiology of Osteoarthritis: Pathomechanisms and Potential Therapeutic Targets

“…Based on multiple genome scans, chromosomes 2, 4, 7, 11 and 16 are now considered as the most likely candidates. Finer linkage analysis narrowed the locus on chromosome 2 to 2q24.3-q31.1, a region which contained 85 known genes [124], but none of these were cartilage-related genes. Other studies suggested that major susceptibility loci were unlikely to be present in this region of 2q [114,125].…”

Osteoarthritis: genetic factors, animal models, mechanisms, and therapies

“…The missense mutation frequency is slightly greater than 2% in patients in the Icelandic population (15). FRZB (2q32.1), which encodes both the chondrogenic regulator secreted frizzled-related protein 3, and CILP (15q22.31) that codes for a cartilage intermediate-layer protein, has also been reported to be associated with OA in females (16,17).…”